

Role of Systemic Immune-Inflammation Index in predicting multi-territorial atherosclerotic disease in peripheral arterial disease: a retrospective cohort study

 Faruk Serhatlıoğlu¹,  Yücel Yılmaz²,  Cemre Tuğrul²,  Halis Yılmaz³,
 Şaban Keleşoğlu⁴

¹Department of Cardiovascular Surgery, Faculty of Medicine, Niğde Ömer Halisdemir University, Niğde, Türkiye

²Department of Cardiology, Kayseri City Training and Research Hospital, Kayseri, Türkiye

³Department of Cardiovascular Surgery, Faculty of Medicine, Erciyes University, Kayseri, Türkiye

⁴Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye

Cite this article: Serhatlıoğlu F, Yılmaz Y, Tuğrul C, Yılmaz H, Keleşoğlu Ş. Role of Systemic Immune-Inflammation Index in predicting multi-territorial atherosclerotic disease in peripheral arterial disease: a retrospective cohort study. *J Cardiol Cardiovasc Surg.* 2025;3(2):35-39.

Corresponding Author: Şaban Keleşoğlu, dr.s.k@hotmail.com

Received: 29/05/2025

Accepted: 26/06/2025

Published: 27/06/2025

ABSTRACT

Aims: Death in patients with peripheral artery disease (PAD) is most often due to coronary artery disease (CAD) or cerebrovascular accidents (CVA). Systemic Immune-Inflammation Index (SII) can be used as a prognostic indicator in different cardiovascular diseases (CVD), including PAD. Our aim in this study was to investigate the predictive value of SII in detecting the coexistence of other CVD in patients with PAD.

Methods: The study included the results of 100 patients who were admitted to the cardiovascular surgery outpatient clinic of our hospital and diagnosed with PAD. PAD, CAD and carotid artery disease (CAAD) were diagnosed by history, physical examination, electrocardiography, duplex ultrasonography and ankle-brachial index (ABI) calculation. SII was determined as neutrophil count multiplied by platelet count and divided by lymphocyte count.

Results: 38 patients had CAAD, 28 had CAD, 19 had only PAD and 15 had all 3 diseases. Platelets levels (285 ± 32.6 vs 234 ± 9.6 , $p < 0.001$), Neutrophils levels (4.9 ± 1.1 vs 4.1 ± 9.8 , $p < 0.001$) and SII levels (4.9 ± 1.1 vs 4.1 ± 1.8 , $p < 0.001$) were compared in both groups with and without other arterial diseases in terms of laboratory findings, while other laboratory findings were not statistically different between both groups ($p < 0.05$).

Conclusion: In our study, we found that those with CAD or CAAD had higher SII levels than those with only PAD.

Keywords: Peripheral artery disease, Systemic Immune-Inflammation Index, multi-territorial atherosclerotic disease

INTRODUCTION

Atherosclerosis is a systemic and inflammatory disease that can involve the entire arterial system. The most common types of atherosclerosis are coronary artery disease (CAD), carotid artery disease (CAAD) and peripheral artery disease (PAD). Studies have shown a link between the severity of atherosclerosis in one arterial territory and the occurrence of atherosclerotic disease in other territories.¹⁻⁴ In patients with CAAD and carotid artery stenosis $\geq 70\%$, 12.5% have PAD and 3.1% have CAD.⁵ 24.5% of patients with PAD and 11.1% of patients with CAD have $\geq 70\%$ carotid artery stenosis.⁶ Therefore, in patients with PAD, the cause of death is mostly due to CAD or cerebrovascular events (CVAs).

The Systemic Immune-Inflammation Index (SII), a parameter of inflammation, is a prognostic indicator of adverse outcomes in various types of cancer.⁷⁻⁹ Furthermore, recent studies have shown that SII, calculated by multiplying neutrophil and

platelet counts multiplied by lymphocyte count divided by lymphocyte count, can be used as a prognostic indicator in different cardiovascular diseases (CVD), including PAD.¹⁰⁻¹³

Our aim in this study was to investigate whether SII can be used to detect the coexistence of other CVDs in patients with PAD.

METHODS

This study was prepared using data obtained from the Medical Master's Thesis titled "Risk of cardiovascular and cerebrovascular diseases in patients with PAD" which we completed in 2007 (Medical Specialization Thesis, Erciyes University, Faculty of Medicine, Department of Surgical Medical Sciences, Department of Cardiovascular Surgery, Kayseri, Türkiye, 2007 / Thesis No:193683). Our hospital's

Institute of Research Ethics reviewed this study involving human subjects. The study was conducted in accordance with the guidelines set out in the Declaration of Helsinki. The ethics committee was informed about the non-experimental design of the retrospective study and approved the study.

The study included the results of 100 patients who were admitted to the cardiovascular surgery outpatient clinic of our hospital and diagnosed with PAD between 02/2005-09/2006. History and physical examination were recorded. PAD, CAD and CAAD were diagnosed by history, physical examination, electrocardiography, duplex ultrasonography and ankle-brachial index (ABI) calculation. The diagnosis of ABI was made by measuring the systolic pressures of the posterior tibial artery and dorsalis pedis and dividing the higher value by the systolic pressure of the brachial artery. Similar measurements were made in both extremities and the lower ABI value was accepted as the patient's ABI value.¹⁴ PAD classification was performed with Rutherford¹⁵ grading. CAAD was investigated by duplex ultrasonography. The intima-media thickness of the right and left internal carotid artery and the bifurcation area was measured and the presence of a lesion was recorded.

Exclusion criteria for the study were as follows: Patients with a history of acute coronary syndrome, anemia, active infection or systemic inflammatory disease, autoimmune or chronic inflammatory disease, heart failure (ejection fraction <40%), chronic anti-inflammatory drug use, impaired liver and kidney function, ABI greater than 1.3.

Blood samples were collected between 08:00-10:00 in the morning. Antecubital venous blood samples were collected in tubes containing tripotassium EDTA as anticoagulant. All routine biochemical tests and hematologic parameters were evaluated using an autoanalyzer. SII was determined as neutrophil count multiplied by platelet count and divided by lymphocyte count.

Statistical Analysis

The data analyses were performed using SPSS 21.0 for Windows (SPSS Inc., Chicago, IL, USA). The distribution of quantitative variables was checked with the Shapiro-Wilk test. Descriptive data were presented as mean±standard deviation and median (interquartile range, IQR) depending on the normality of the distribution. Median and quartile ranges were given for non-normally distributed variables. An independent samples t-test was used for the comparison of quantitative variables with normal distribution, and the Mann-Whitney U test was used for quantitative variables without normal distribution. Categorical variables were compared using the Chi-square test. p values below 0.05 were accepted to show statistically significant.

RESULTS

A total of 100 patients were included in the study. The mean age was 59.8±13.1 years. 93 of them were male. 58 patients were smokers. 38 patients had CAAD, 28 had CAD, 19 had only PAD and 15 had all 3 diseases. Diabetes mellitus (DM)

was present in 32 patients and hypertension (HT) was present in 46 patients. Patients were divided into 2 groups: those with PAD only and those with concomitant disease in other arterial systems. When demographic characteristics were compared, no difference was observed between the groups in terms of age, gender, history of DM/HT/dyslipidemia, smoking history, body-mass index, heart rate, blood pressure measurements and Rutherford classification ($p<0.05$) (**Table 1**).

Table 1. Demographic characteristics of the study populations

	Another artery disease		p value
	Yes (n=81)	No (n=19)	
Variables			
Age (years)	57.8±8.6	61.2±10.1	0.502
Women gender (n, %)	5 (6.2%)	2 (10.5%)	0.455
Diabetes mellitus (n, %)	26 (32.1%)	6 (31.6%)	0.655
Hypertension (n, %)	36 (44.4%)	10 (52.6%)	0.672
Dyslipidemia	19 (23.5 %)	4 (21%)	0.391
Carotid artery disease (n, %)	38 (46.9%)	0 (46.3%)	-
Coronary artery disease (n, %)	28 (34.6%)	0 (6.9%)	-
Smoking (n, %)	47 (58%)	11 (57.9%)	0.145
Body-mass index (kg/m ²)	28.3±4.1	29.5±4.8	0.931
Systolic blood pressure (mmHg)	133.6±13.7	132.8±15	0.654
Diastolic blood pressure (mmHg)	81.7±8.7	84±9.9	0.331
Heart rate	88.1±14.7	92.3± 8.5	0.07
Rutherford classifications (≥3)	22 (27.2%)	5 (26.3%)	0.717

Platelets levels (285±32.6 vs 234±9.6, $p<0.001$), Neutrophils levels (4.9±1.1 vs 4.1±9.8, $p<0.001$) and SII levels (4.9±1.1 vs 4.1±1.8, $p<0.001$) were compared in both groups with and without other arterial diseases in terms of laboratory findings, while other laboratory findings were not statistically different between both groups ($p<0.05$) (**Table 2**).

Table 2. Laboratory findings of the study populations

	Another artery disease		p value
	Yes (n=81)	No (n=19)	
Number of patients			
Glucose (mg/dl)	100.5±33.8	91.5±32.1	0.566
Serum creatinine (mg/dl)	0.91±0.41	0.95±0.39	0.620
AST (U/L)	25.2±7.3	22.7±7.9	0.667
ALT (U/L)	27.9±7.5	25.4±7.9	0.723
LDL cholesterol (mg/dl)	149.6±41.1	146.5±53.6	0.089
Hemoglobin (mg/dl)	13.5±2.4	13.8±2.5	0.606
Platelet (10 ³ /μL)	285±32.6	234±9.6	<0.001
White blood cell (10 ³ /μL)	9.4±6.3	8.3±4.1	0.132
Neutrophil (10 ³ /μL)	4.9±1.1	4.1±1.8	<0.001
Lymphocyte (10 ³ /μL)	2.09±0.7	2.25±0.8	0.056
SII	699 (443-1139)	431 (299-599)	<0.02

AST: Aspartate aminotransferase, ALT: Alanine aminotransferase (U/L), LDL: Low-density lipoprotein, SII: Systemic Immune-Inflammation Index

DISCUSSION

In this study, we reached results that may suggest that SII, which is considered a good inflammatory marker, can be used to predict the presence of CAAD and CAD in patients with PAD.

Peripheral arterial disease (PAD) is a group of diseases that are common and usually related to atherosclerosis, causing morbidity and mortality. It may occur due to living conditions, habits and occupation.^{16,17} A significant proportion of patients with PAD have been reported to have CAD.¹⁸⁻²⁰ Some autopsy studies have shown that almost all patients with severe lower extremity PAD have extensive atherosclerotic disease in the coronary arteries.²⁰ In addition, a significant association between low ABI values and CAAD has been shown.²¹

As the severity of inflammation increases in the host, it is obvious that inflammation markers will increase accordingly. PAD patients had higher neutrophil counts than CAD patients, suggesting higher inflammation and thus more atherosclerosis in PAD than in CAD patients.^{22,23} Bravetti et al.²² showed that CAD patients with concurrent PAD had higher neutrophil counts than those with CAD alone. Similarly, Rossi et al.²⁴ in another study showed that blood leukocyte counts in patients with acute myocardial infarction increased in proportion to the plaque density in the carotid arteries. Vidacovic et al.²⁵ found that patients with atherosclerotic vascular disease had more elevated CRP levels when each peripheral arterial territory was included. In our study, we found that blood neutrophil counts were higher in patients with PAD, regardless of which arterial segment had atherosclerotic disease.

The ABI is an inexpensive and readily available test for the diagnosis of PAD. It has shown improved mortality prediction when PAD is determined to be present based on an ABI \leq 0.9 and when combined with NLR.²⁶ A higher neutrophil count has been shown to be associated with major adverse cardiovascular events, death and a composite of myocardial infarction, stroke and death in patients with PAD.²⁷ Aykan et al.²⁸ claimed in a study that NLR is associated with the prevalence and complexity of PAD. A review by Bhat et al.²⁹ also evaluated that NLR was an independent predictor of early and mid-term amputation in patients with acute limb ischemia after embolectomy, a predictor of mortality and/or major amputation in critical limb ischemia, and an independent predictor of PAD severity. Songur et al.³⁰ found a correlation between PLR and higher amputation rate in patients with PAD. In addition, Yalim et al.³¹ also claimed a correlation between PLR and NLR in multisite atherosclerosis.

There is a growing body of evidence suggesting that SII, calculated with three, is a stronger predictor of immune and inflammatory status in patients than single-component (neutrophils, lymphocytes, platelets) and two-component (PLR and NLR) inflammatory markers. There are studies showing that high SII levels are superior to NLR and PLR in predicting the risk of clinical outcomes in various diseases.^{7,9,11,12} In addition, Zhang et al.³² found that elevated SII on admission was independently associated with

the presence of plaque thickness and ulceration in acute ischemic stroke. Aktemur et al.³³ found that SII is an effective predictor of mortality risk in patients with iliac artery disease undergoing percutaneous intervention. Higher SII may indicate the possibility of more complex lower extremity arterial disease.¹³ Oflar et al.¹³ claimed that increased SII levels are an independent predictor of CAAD severity. In our study, we found that those with CAD or CAAD had higher SII levels than those with only PAD. When evaluated together with the literature, it can be speculated that individuals with more inflammation have higher SII levels. Although NLR and PLR levels were not evaluated, when considered together with other study results, it can be concluded that SII is a better inflammatory marker for the detection of those with more extensive atherosclerotic disease.

Considering our results in terms of physiopathologic mechanisms, neutrophils invade the plaque and initiate and/or exacerbate tissue damage and inflammation by directly and indirectly affecting both endothelial and smooth muscle cells through the mediators they secrete.^{35,36} With endothelial damage, monocyte/lymphocyte migration to the subendothelial region and subsequent foam cells, fatty streaks, which are the first stage of atherosclerotic plaques, are formed, and then the atherosclerotic plaque progresses with the continuation of slow inflammation. In addition, proteolytic enzymes and growth factors released from monocytes (foam cells) and lymphocytes have important roles in damage and repair.³⁷ Lymphopenia occurs due to physiological stress and a mechanism such as decreased cell production, tissue-level redistribution or cell apoptosis.³⁸ With increased lymphocyte apoptosis within the atherosclerotic plaque, plaque development progresses and destabilization occurs within the plaque.³⁸ Platelets are a key component of the cellular process in hemostasis, as well as being important in maintaining vascular integrity in the absence of injury and protecting against spontaneous bleeding.³⁹ Platelets regulate lymphocyte activation and influence the function of lymphocyte subpopulations. They also contribute to the migration and proliferation of smooth muscle cells.^{37,40,41}

Limitations

This study has some limitations. The study included a small number of patients and was a single-center, retrospective study. The number of patients in our study may have been insufficient and our data set is quite old. This may have caused unintentional bias in our statistical results. In our study, we only evaluated the presence of CAAD. Therefore, we did not evaluate the carotid artery stenosis rate. Considering that the severity of carotid artery stenosis is related to LVH, this can be considered a limitation of our study. SII levels were calculated only during hospital admission. Furthermore, parameters potentially affecting atherosclerosis, such as VEGF, TGF α - β , and NO, were not measured and the lack of a follow-up study does not provide insight into the long-term changes and effects of SII.

CONCLUSION

Neutrophils and platelets positively influence inflammation and the development of atherosclerotic plaques, whereas a decrease in lymphocytes has a negative effect. These

findings suggest that SII may serve as a more accurate and comprehensive measure to predict immunologic and inflammatory/anti-inflammatory states in the individual. The results of the present study suggest that SII, a useful, simple, easily measurable and inexpensive indicator of inflammatory status, is a powerful inflammatory marker for predicting additional arterial system diseases (CAD and CAAD) in PAD patients. Larger and multicenter studies are needed to better analyze all possible predictors of disease development.

ETHICAL DECLARATIONS

Ethics Committee Approval

This study was prepared using data obtained from the Medical Master's Thesis titled "Risk of cardiovascular and cerebrovascular diseases in patients with PAD" which we completed in 2007 (Medical Specialization Thesis, Erciyes University, Faculty of Medicine, Department of Surgical Medical Sciences, Department of Cardiovascular Surgery, Kayseri, Türkiye, 2007 / Thesis No:193683).

Informed Consent

Because the study was designed retrospectively, no written informed consent form was obtained from patients.

Referee Evaluation Process

Externally peer-reviewed.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Financial Disclosure

The authors declared that this study has received no financial support.

Author Contributions

All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version.

REFERENCES

1. Tanimoto S, Ikari Y, Tanabe K, et al. Prevalence of carotid artery stenosis in patients with coronary artery disease in Japanese population. *Stroke*. 2005;36(10):2094-2098. doi:10.1161/01.STR.0000185337.82019.9e
2. Kallikazaros I, Tsioufis C, Sideris S, Stefanadis C, Toutouzas P. Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain. *Stroke*. 1999;30(5):1002-1007. doi:10.1161/01.str.30.5.1002
3. Steinvil A, Sadeh B, Arbel Y, et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. *J Am Coll Cardiol*. 2011;57(7):779-783. doi:10.1016/j.jacc.2010.09.047
4. Qureshi AI, Alexandrov AV, Tegeler CH, et al. Guidelines for screening of extracranial carotid artery disease: a statement for healthcare professionals from the multidisciplinary practice guidelines committee of the American Society of Neuroimaging; cosponsored by the Society of Vascular and Interventional Neurology. *J Neuroimaging*. 2007;17(1):19-47. doi:10.1111/j.1552-6569.2006.00085.x
5. Kurvers HA, van der Graaf Y, Blankensteijn JD, Visseren FLJ, Eikelboom BC, SMART Study Group. Screening for asymptomatic internal carotid artery stenosis and aneurysm of the abdominal aorta: comparing the yield between patients with manifest atherosclerosis and patients with risk factors for atherosclerosis only. *J Vasc Surg*. 2003;37(6):1226-1233. doi:10.1016/s0741-5214(02)75140-9
6. Cheng SW, Wu LL, Lau H, Ting AC, Wong J. Prevalence of significant carotid stenosis in Chinese patients with peripheral and coronary artery disease. *Aust N Z J Surg*. 1999;69(1):44-47. doi:10.1046/j.1440-1622.1999.01501.x
7. Ji Y, Wang H. Prognostic prediction of Systemic Immune-Inflammation Index for patients with gynecological and breast cancers: a meta-analysis. *World J Surg Oncol*. 2020;18(1):197. doi:10.1186/s12957-020-01974-w
8. Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of Systemic Immune-Inflammation Index in patients with urologic cancers: a meta-analysis. *Cancer Cell Int*. 2020;20:499. doi:10.1186/s12935-020-01590-4
9. Zhang Y, Lin S, Yang X, Wang R, Luo L. Prognostic value of pretreatment Systemic Immune-Inflammation Index in patients with gastrointestinal cancers. *J Cell Physiol*. 2019;234(5):5555-5563. doi:10.1002/jcp.27373
10. Huang J, Zhang Q, Wang R, et al. Systemic Immune-Inflammation Index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. *Med Sci Monit*. 2019;25:9690-9701. doi:10.12659/MSM.919802
11. Yang YL, Wu CH, Hsu PF, et al. Systemic Immune-Inflammation Index (SII) predicted clinical outcome in patients with coronary artery disease. *Eur J Clin Invest*. 2020;50(5):e13230. doi:10.1111/eci.13230
12. Huang T, Peng Q, Zhang Y, Zhu Z, Fan X. The Systemic Immune-Inflammation Index (SII) and coronary artery lesions in Kawasaki disease. *Clin Exp Med*. 2024;24(1):4. doi:10.1007/s10238-023-01265-0
13. Ofar E, Akdeniz E, Yıldız C, et al. Evaluation of systemic immune-inflammation index for predicting severity of lower extremity arterial disease. *Vascular*. 2024;32(4):797-803. doi:10.1177/17085381241251772
14. Decrinis M, Doder S, Stark G, Pilger E. A prospective evaluation of sensitivity and specificity of the ankle/brachial index in the follow-up of superficial femoral artery occlusions treated by angioplasty. *Clin Invest*. 1994;72(8):592-597. doi:10.1007/BF00227451
15. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg*. 1997;26(3):517-538. doi:10.1016/s0741-5214(97)70045-4
16. Scalise E, Costa D, Gallelli G, et al. Biomarkers and social determinants in atherosclerotic arterial diseases: a scoping review. *Ann Vasc Surg*. 2025;113:41-63. doi:10.1016/j.avsg.2024.12.076
17. Khan H, Girdhar NR, Massin SZ, et al. Current prognostic biomarkers for peripheral arterial disease: a comprehensive systematic review of the literature. *Metabolites*. 2025;15(4):224. doi:10.3390/metabol15040224
18. Gersh BJ, Rihal CS, Rooke TW, Ballard DJ. Evaluation and management of patients with both peripheral vascular and coronary artery disease. *J Am Coll Cardiol*. 1991;18(1):203-214. doi:10.1016/s0735-1097(10)80241-4
19. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Foster ED. Coronary artery disease in diabetic and nondiabetic patients with lower extremity arterial disease: a report from the Coronary Artery Surgery Study Registry. *Am Heart J*. 1998;135(6 Pt 1):1055-1062. doi:10.1016/s0002-8703(98)70072-9
20. Mautner SL, Mautner GC, Hunsberger SA, Roberts WC. Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men. *Am J Cardiol*. 1992;70(18):1380-1387. doi:10.1016/0002-9149(92)90285-7
21. Murabito JM, Evans JC, Larson MG, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med*. 2003;163(16):1939-1942. doi:10.1001/archinte.163.16.1939
22. Brevetti G, Piscione F, Silvestro A, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. *Thromb Haemost*. 2003;89(6):1058-1063.
23. Erren M, Reinecke H, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. *Arterioscler Thromb Vasc Biol*. 1999;19(10):2355-2363. doi:10.1161/01.atv.19.10.2355
24. Rossi A, Franceschini L, Fusaro M, et al. Carotid atherosclerotic plaque instability in patients with acute myocardial infarction. *Int J Cardiol*. 2006;111(2):263-266. doi:10.1016/j.ijcard.2005.08.030
25. Vidakovic R, Schouten O, Kuiper R, et al. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2009;38(4):435-440. doi:10.1016/j.ejvs.2009.05.006
26. Amrock SM, Weitzman M. Multiple biomarkers for mortality prediction in peripheral arterial disease. *Vasc Med*. 2016;21(2):105-112. doi:10.1177/1358863X15621797
27. Haumer M, Amighi J, Exner M, et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. *J Vasc Surg*. 2005;41(4):610-617. doi:10.1016/j.jvs.2005.01.013

28. Aykan AÇ, Hatem E, Kalaycıoğlu E, et al. Neutrophil-to-lymphocyte ratio may be a marker of peripheral artery disease complexity. *Anatol J Cardiol*. 2016;16(7):497-503. doi:10.5152/AnatolJCardiol.2015.6240
29. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. *Expert Rev Cardiovasc Ther*. 2013; 11(1):55-59. doi:10.1586/erc.12.159
30. Songur M, Simsek E, Faruk O, Kavasoglu K, Alagha S, Karahan M. The platelet-lymphocyte ratio predict the risk of amputation in critical limb ischemia. *J Vasc Med Surg*. 2014;02(04):158. doi:10.4172/2329-6925.1000158
31. Yalın Z, Aldemir M, Emren SV. Association of inflammatory markers with multisite artery disease in patients with peripheral arterial disease. *Clin Invest Arterioscler*. 2021;33(2):55-61. doi:10.1016/j.arteri.2020.08.002
32. Zhang L, Xu X, Zhang X, Jiang S, Hui P. Systemic Immune-Inflammation Index is associated with ulcerative plaque in patients with acute ischemic stroke: a single center exploratory study. *J Clin Ultrasound*. 2024;52(3):295-304. doi:10.1002/jcu.23632
33. Aktemur T, Demirci G, Tasbulak O, et al. A simple predictor for long-term mortality after percutaneous iliac artery intervention: Systemic Immune Inflammatory Index. *Ann Vasc Surg*. 2023;96:276-283. doi:10.1016/j.avsg.2023.03.012
34. Kelesoglu S, Yilmaz Y, Elcik D, et al. Increased serum Systemic Immune-Inflammation Index is independently associated with severity of carotid artery stenosis. *Angiology*. 2023;74(8):790-797. doi:10.1177/00033197221144934
35. Candemir M, Kiziltunç E, Nurkoç S, Şahinarslan A. Relationship between Systemic Immune-Inflammation Index (SII) and the severity of stable coronary artery disease. *Angiology*. 2021;72(6):575-581. doi:10.1177/0003319720987743
36. Balta S, Celik T, Mikhailidis DP, et al. The relation between atherosclerosis and the neutrophil-lymphocyte ratio. *Clin Appl Thromb Hemost*. 2016;22(5):405-411. doi:10.1177/1076029615569568
37. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med*. 1999; 340(2):115-126. doi:10.1056/NEJM199901143400207
38. Núñez J, Sanchis J, Bodí V, et al. Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levels. *Atherosclerosis*. 2009;206(1):251-257. doi:10.1016/j.atherosclerosis.2009.01.029
39. Li N. Platelet-lymphocyte cross-talk. *J Leukoc Biol*. 2008;83(5):1069-1078. doi:10.1189/jlb.0907615
40. Demirtas S, Karahan O, Yazici S, et al. The relationship between complete blood count parameters and Fontaine's Stages in patients with peripheral arterial disease. *Vascular*. 2014;22(6):427-431. doi:10.1177/1708538114522227
41. Duran M, Gunebakmaz O, Uysal OK, et al. Relation between mean platelet volume and coronary collateral vessels in patients with acute coronary syndromes. *J Cardiol*. 2013;61(4):295-298. doi:10.1016/j.jjcc.2012.12.011